



ISSN 2456-3110

Vol 2 · Issue 3

May - June 2017

Journal of
**Ayurveda and Integrated
Medical Sciences**

www.jaims.in

JAIMS



Charaka
Publications

Indexed

Cholesterol & its Ayurvedic Complement - Depicting its role in Pathogenesis as well as Management of Diabetes

Divya Kajaria

Assistant Professor, Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.

ABSTRACT

Role of cholesterol in the pathogenesis of diabetes is the emergent area of research with full of potential; it not only open a vast area of therapeutic interventions but also can change the prevailing treatment modality. Ayurveda, the Indian system of medicine materialize the concept of lipocentric approach for the management of diabetes even thousands of years back. According to Ayurveda, the natural properties of lipid are deranged that causes diabetes. It may prove beneficial to quest the search of herbal remedies that can harmonize the lipid balance and uproot the pathogenesis. In the presenting review article, role of cholesterol in the pathogenesis of diabetes is discussed along with detailed description of Ayurvedic concepts regarding pathogenesis and a brief description of herbal management.

Key words: Lipids, Prameha, Kapha, Herbs, Rasayana.

INTRODUCTION

Global burden due to diabetes rising steeply affecting >422 million individuals worldwide.^[1] Its alarming prevalence has dreaded impact on health sector due to poor quality of life caused by long term complications and associated medical cost. The most disgusting fact related to diabetes is that despite of tremendous effort made by researchers there is still no ray of relief is evident in the near future. More than 90% of all cases accounts for type 2 diabetes and is characterized by insulin resistance as well as pancreatic B cell dysfunction (to what extent B cell are involved in the pathogenesis is disputable).^[2] Alteration in pancreatic B cell function causes impaired insulin secretory response to the glucose

and this characterized transition from the pre-diabetic to the diabetic state.^[3] Recent researches have shown that hyperlipidemia plays decisive role in the pathogenesis of B cell dysfunction.^[4] Association of dyslipidemia with diabetes is already well established and role of elevated free fatty acids (FFAs) is well defined and studied extensively^[5] but now one more link is added in this pathogenesis. This new linkage is hunting the role of cholesterol in glucose-stimulated insulin secretion from pancreatic B cell. Cholesterol has assigned many important functions in cellular domain. One of its major functions is regulation of signal transduction through membrane microdomain and gene expression through cholesterol-activated transcription factors.^[6] Intracellular cholesterol regulates glucose metabolism and gene expression in adipocytes.^[7] Disturb metabolism of cholesterol (involving synthesis, storage or excretion) could result in disruption of any one pathway of glucose stimulated insulin secretion to partial or complete loss of secretory functions of pancreatic B cell. Cholesterol is a very important biomolecule with diverse functions ranging from membrane trafficking and signal transduction to its role in embryogenesis.^[8] With the advancement in science our insight for this miraculous biomolecule also enhances lifting the veil from its physiological and pathological functions. Cholesterol

Address for correspondence:

Dr. Divya Kajaria

Assistant Professor, Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.

E-mail: divyakajaria@gmail.com

Submission Date : 05/06/2017 Accepted Date: 25/06/2017

Access this article online

Quick Response Code



Website: www.jaims.in

DOI: 10.21760/jaims.v2i3.8220

is present in tissues and in plasma either as free cholesterol or as a storage form, combined with a long chain fatty acid as cholesteryl ester. Cholesterol is required to build as well as to maintain cell membrane; it imparts membrane fluidity and mobility.^[9] Within the cell membrane it also helps in intracellular transport, cell signaling and nerve conduction.^[10] It form lipid rafts along with sphingolipids for cellular signaling.^[11] Its de novo synthesis is a complex process and tightly regulated by hormones, HMG Co-A reductase and gene transcription.^[12] Uptake of cholesterol is measured by sterol - sensing protein. Binding of cholesterol to sterol sensing protein initiates degradation of HMG-Co A reductase.^[13] The most important step in its metabolism is its transport in plasma. In plasma, both forms are transported in lipoproteins. Plasma low-density lipoprotein (LDL) is the vehicle for uptake of cholesterol and cholesteryl ester into many tissues. Free cholesterol is removed from tissues by plasma high - density lipoprotein (HDL) and transported to the liver, where it is eliminated from the body either unchanged or after conversion to bile acids in the process known as reverse cholesterol transport. Membrane fluidity as well as curvature is strongly modulated by the amount of cholesterol present in the membrane and therefore membrane microdomains of B cell can enhance cell signaling by depleting or overloading cholesterol and modulate glucose stimulated insulin secretion (GSIS).^[14] Cholesterol alteration also affects glucose metabolism involving glucokinase.^[15] Research studies have shown that excess cellular cholesterol is directly linked to reduced glucose sensitive insulin secretion and also that normal secretion can be restored by cholesterol depletion.^[16] Elevated serum cholesterol causes increased cholesterol in pancreatic B cells that directly and significantly modulate the insulin secretion independent of FFA levels. Thus, it is now postulated that cellular cholesterol will be a potential target for therapeutic intervention aimed to preserve or improve pancreatic B cell functioning through modulating GSIS. Fryris et.al. postulated that cholesterol is a key determinant of beta cell membrane organization and cell survival.^[17] They

suggest that different lipoprotein classes have varying effect on beta cell function and survival. Further they concluded that cholesterol can cause B cell loss if allowed to accumulate in cell in an unregulated manner and therefore it is utmost important to maintain beta cell cholesterol homeostasis. C. Langhi and B. Carjou in their article also stated that dysregulation of plasma lipoproteins with increased TG content in pancreatic B cell leads to lipotoxicity and subsequently cell death.^[18] They also emphasize the role of cholesterol modulators like ATP binding cassette transporter A1 and LDL receptor.

Complement of Cholesterol in Ayurveda

Kapha is known by a number of synonyms. Of these, *Shleshma*, *Bala*, *Ojas*, *Mala* and *Papma* are important. The former three refer to its normal states of functioning, while latter two to abnormal states. *Kapha* is the product of water. The synonym, *Shleshma*, which is used as frequently as the term *Kapha* is derived from the root 'Shlish Alingane' meaning *Shlish* is to embrace, to cohere or to keep together. Charaka considers that *Kapha*, in its normal states of functioning represent a potential source of strength and resistance to disease and decay i.e. *Bala* and *Ojas*. These terms refer to that power or force which resists the factors of decay and disease. *Bala* may be *Sahaja* (innate, natural or inherited), *Kalaja* (seasonal) and *Yuktikrita* (acquired). Sushruta has used the term *Bala* to signify *Ojas* and stated that "Bala is the power (of the body) sufficient to resist disease".

Relation between *Kapha* (cholesterol) and *Meda* (adipose tissues)

It has been stated that , among seven *Dhatus* (the seven kinds of primary tissue - elements), *Rasa* (lymphoid plasma), *Mamsa* (muscle tissues), *Medas* (adipose tissues), *Majja* (marrow tissues) and *Sukra* (the male reproductive element) are seats of *Kapha*. It has also been stated that the *Ojas*, a synonym of *Kapha*, is an essential factor of all *Dhatus* (tissues) of the body.

Table 1: Showing correlation between Lipids and Kapha on the basis of their physical properties and biological functions

Lipids		Kapha	
Physical characteristic	Biological functions	Physical characteristic	Biological functions
Lipids are group of natural occurring molecules that include fat, waxes, sterols etc., and lipid is frequently used as a synonym for fats. Lipid molecules with long carbon chains have high molecular weight like cholesterol have molar mass 386.65 g/mol, fat have 228.98 g/mol and fatty acids like oleic acid have molar mass 282.46	Storage of energy. Synthesis of cell membranes. Maintaining fluidity and flexibility of the membrane. Regulation of steroid hormone. Act as intracellular signaling molecule. Maintenance of body temperature. Play an important role in pain, fever, inflammation and blood clotting.	<i>Sneha</i> , (unctuousness), <i>Guru</i> (heavy), <i>Shita</i> (cool), <i>Mrudu</i> (soft), <i>Snigdha</i> (viscous), <i>Shouklya</i> (whitishness), <i>Madhura</i> (sweet), <i>Sara</i> (firm), <i>Sthira</i> (stable, sturdy) and <i>Pichchila</i> (slimy), <i>Sandra</i> (dense formed, firm or compact).	<i>Snehana</i> (the promotion of unctuousness), <i>Bandhana</i> (keeping together), <i>Sthiratwa</i> (providing stability), <i>Gaurava</i> (heaviness), <i>Vrishatwa</i> (providing sexual potency), <i>Ropanam</i> (promotion of healing and reparative processes), <i>Puranam</i> (fulfilment or providing energy), <i>Bhrimhanam</i> (promotion of growth, regeneration), <i>Tarpanam</i> (providing nutrition), <i>Sthairyakriti</i> (confers

g/mol, etc. Lipids are oily to the touch; they are soft greasy/ slippery or viscous substance.			stability and firmness), <i>Visarga Karma</i> (anabolic activity)
--	--	--	---

Table 2: Relation between types of Kapha, Lipids and related diseases

Types of Kapha	Lipids	Disease due to vitiation of Kapha/ lipids
<i>Kledaka</i>	Cholesterol present in bile acids	<i>Grahani</i> (Steatorrhea), <i>Pandu</i> (spur cell anemia) ^[3] <i>Kamala</i> (obstructive jaundice, intrahepatic cholestasis) etc.
<i>Avalambaka</i>	Neutral lipids including cholesterol, phospholipids, present in heart muscles mitochondria and microsomes. ^[4] HDL, LDL, VLDL and cholesterol present in blood.	<i>Hridroga</i> (Cardiomyopathies, Coronary artery disease,, Myocardial Infarction, etc.) Dyslipidemia,
<i>Slesmaka</i>	Cholesterol and phospholipids present in synovial fluid	<i>Amavata</i> (Rheumatoid Arthritis), <i>Sandhivishlesha</i> (Osteoarthritis), <i>Kaphaja Vatarakta</i> (Psoriatic arthritis)
<i>Tarpaka</i>	glycerophospholipids, sphingolipids, and cholesterol present in	<i>Dhriti – Smriti bhransa</i> (memory disorder,

	CSF and cholesterol, phospholipids, and glycosphingolipids in myelin sheath	Alzheimer’s disease, Neurodegenerative diseases, Smith-Lemli-Opitz syndrome, Niemann-Pick type- C disease).
<i>Bodhaka</i>	fatty acids, cholesterol, monoglycerides, diglycerides and triglycerides present in saliva.	

Fig. 1: Diagrammatic representation showing Bio-constituents of *Kapha* and *Meda Dhatu*.



Fig. 2: Biological Functions of Lipids.




Fig. 3: Role of *Kapha* in Metabolism of Lipids.






Fig. 4: Biological functions of *Kapha*.





Vitiated Kapha causing Prameha (Diabetes Mellitus)

Charaka Samhita has firmly established the relationship between obesity and *Prameha*. The role of *Meda* (fat/ adipose tissue) is of great importance in the pathogenesis of *Prameha*. Its role is not only as *Dushya* (disturbed functioning of the *Dhatu*s), but something more than that. According to Charaka Samhita, *Bahudrava Shlema* (*Kapha* that contains too much liquid) joins and affects *Meda*, causing it to become *Abadha* (unobstructed or fluid) in nature.^[19] This form of *Meda* has been described as acting on *Mamsa* (muscle tissue), thereby increasing the volume of body fluid. This has been described as *Sharira- Kleda* (body fluid) in Ayurveda. Thus, excess water in the blood causes increased diuresis. This route of pathogenesis for *Prameha* is closely related to obesity.

The role of *Meda* (fat/adipose tissues) is of great importance in the pathogenesis of *Prameha*. Its role is not as *Dushya* (disturbed functioning of the *Dhatu*s), but something more than that. According to Charaka Samhita, *Bahudrava Shleshma* (*Kapha* that contains too much liquid) joins and affects *Meda*, causing it to become *Abaddha* (unobstructed or fluid) in Ayurveda. This has been described as *Sharira- Kleda* (body of fluid) in Ayurveda. Thus, excess water in the blood causes increased diuresis. It is very important to elaborate the term *Bahudrava Slesma. Sleshma/*

Kapha is one among the three basic humor regulating all physiological and psychological process in the living organism. At its normal state it cause binding of body tissues i.e. maintain the tissues integrity, represent the normal cell mediated immunity etc. *Bahudrava* means that *Kapha* loses its natural properties and get vitiated, it is worthful to mention here that this derangement may be acquired or congenital, Whatever may be the cause this vitiated *Kapha* is unable to perform its normal functions. Describing the physical properties of *Kapha* it is mentioned that it is unctuous in touch and look like *Ghrta* (ghee). Thus it can be said that *Kapha* in body represents lipid components of the body and vitiated *Kapha* can be correlated with dyslipidemia. Role of dyslipidemia and metabolic abnormalities in the pathogenesis of diabetes is very obvious and well elaborated in modern medicine. Among the metabolic abnormalities that commonly accompany diabetes are disturbances in the production and clearance of plasma lipoproteins. Moreover, development of dyslipidemia may be a harbinger of future diabetes. A characteristic pattern, termed diabetic dyslipidemia, consists of low high density lipoprotein (HDL), increased triglycerides, and postprandial lipemia. This pattern is most frequently seen in type 2 diabetes and may be a treatable risk factor for subsequent cardiovascular disease.

Management of Kaphaja disorders

Use of Herbs

Acharya Charaka mentioned a group of ten drugs that should be used for scraping the excessive fat known as *Lekhaniya drugs*. All these ten drugs are found to have hypolipidemic effects *Musta* (*Cyperus rotandus* Linn.), *Kustha* (*Saussurea lappa* C.B.Clarke), *Haridra* (*Curcuma longa* Linn.), *Daruharidra* (*Berberis aristata* D.C.), *Vaca* (*Acorus calamus* Linn.), *Ativisa* (*Aconitum heterophyllum* Wall.), *Katurohani* (*Picrorhiza kurroa* Royle ex Benth.), *Citraka* (*Plumbago zeylanica* Linn.), *Cirabilva* (*Pongamia pinnata* Merr.) and *Hemavati* (*Iris versicolor*) are ten drugs given by Acharya Caraka to reduce body fats. Charaka Samhita has been claimed to be effective in *Medoroga* (lipid disorder).

1. **Musta (*Cyperus rotandus* Linn.):** *Nagarmotha* or *Musta* is reported to have significant hypolipidaemic activity.^[20] Administration of *C. rotundus* extract at 250 mg/kg and 500 mg/kg as well as the hypolipidemic drug, simvastatin at 5 mg/kg found to caused a significant ($p = 0.05$) decrease in serum total cholesterol and LDL cholesterol. Triglyceride was also significantly reduced at 500mg/kg extract and simvastatin at 5mg/kg but the decrease at 250 mg/kg extract was not significant. In this study the level of HDL cholesterol was significantly ($p = .05$) increased in the treatment groups.^[21] *Nagarmotha* is found to increase reabsorption of bile salt and thereby regularize the hepatic liposynthesis it reverse cholesterol transport pathway, in which HDL cholesterol induces an efflux of excess accumulated cellular cholesterol and prevents the generation of an oxidatively modified LDL. *C. rotundus* is found to reverted the age associated increased level of total cholesterol and LDL cholesterol to the level of young control rats.^[22] The beneficial effect of cholesterol lowering activity of *C. rotundus* could be attributed to β -sitosterol and saponin that are well known for their cardioprotective properties by lowering the cholesterol.^{[23],[24]}
2. **Kustha (*Saussurea lappa* C.B.Clarke):** *S. lappa* Clarke of Compositae is known as *Kushta* in Sanskrit. It is a tall, robust, perennial herb distributed in Kashmir. The roots are hot, bitter, sweetish, pungent, and flattering. It is used as an analgesic, digestive, aphrodisiac and diuretic. Some authors have reported that the roots of this plant possess cortisol-lowering effect.^{[25],[26]} Traditionally, aqueous extract of the root of *S. lappa* was used for its anti-anginal effect.^[27] The hot water extract of the roots has been traditionally used for the treatment of asthma,^{[27],[28]} inflammations and rheumatism.^{[29],[30]} Ethanollic extract of *S. Lappa* showed significant hypolipidemic activity which may be due to presence of tannins, triterpenes, alkaloids, inulin, essential oil in its root. Treatment with ethanollic extract of *S. Lappa* significantly reduced serum and tissue cholesterol, LDL-C. HDL-C level in both serum and tissue are significantly increased by ethanollic extract of *S. Lappa*.^[31] *Saussurea lappa* is one of the antioxidant - rich medicinal plants.
3. **Haridra (*Curcuma longa* Linn.):** The metabolite of *C. longa* – curcumin (0.5%) is found to significantly decrease the cholesterol, LDL, VLDL, triglycerides and phospholipids in Streptozotocin-induced diabetic rats. In a parallel study, wherein diabetic animals were maintained on a high cholesterol diet, the extents of hypercholesterolemia and phospholipidemia were still higher compared to those maintained on control diet. Curcumin exhibited lowering of cholesterol and phospholipid in these animals also. Liver cholesterol, triglyceride and phospholipid contents were elevated under diabetic conditions. Dietary curcumin showed a distinct tendency to counter these changes in lipid fractions of liver. This effect of curcumin was also seen in diabetic animals maintained on high cholesterol diet. Dietary curcumin also showed significant countering of renal cholesterol and triglycerides elevated in diabetic rats. Curcumin enhances liver cholesterol catabolism as evidenced by increase in hepatic cholesterol-7a-hydroxylase activity.^[32-37]
4. **Daruharidra (*Berberis aristata* D.C.):** According to Ayurvedic pharmacopeia of India, *B. aristata* DC is used in diabetes. Diabetes mellitus is one of the most common chronic diseases and is associated with hyperlipidemia and co-morbidities such as obesity and hypertension. *B. aristata* at the dose of 25 mg/kg revealed a significant reduction in serum cholesterol, triglycerides and LDL-C.^[38] The hypolipidemic effects of *B. aristata* may be due to the presence of berberine alkaloid, since berberine act at both endothelium and the underlying vascular smooth muscle to induce relaxation.^[39] The strong antihyperglycemic effect of methanolic extract of *B. aristata* DC stem could indirectly be related to beneficial

action against the abnormal high concentration of serum lipids observed in diabetes rats.^[40]

5. **Vaca (*Acorus calamus* Linn.):** *A. calamus*. Linn. (Araceae), commonly known as “sweet flag” or “calamus”, is a semiaquatic, perennial, aromatic herb with creeping rhizomes. *A. calamus*. Linn. has been used as traditional Indian and Chinese prescriptions for its beneficial effects on memory disorder, learning performance, lipid peroxide content, and anti-aging and anticholinergic activity. Moreover, pharmacological studies have revealed that *Acorus*. rhizome and its constituents, particularly α - and β -asarone, possess a wide range of pharmacological activities such as sedative, CNS depressant, behavior modifying, anticonvulsant, acetylcholinesterase inhibitory, memory enhancing, anti-inflammatory, antioxidant, antispasmodic, cardiovascular, hypolipidemic, immuno suppressive, cytoprotective, antidiarrheal, antimicrobial, anthelmintic, insecticidal, adulticidal, diuretic, antioxidant, genotoxic, and mutagenic activities.^[41] Administration of the 50% ethanolic extract (100 and 200 mg/kg) as well as saponins (10 mg/kg) isolated from the extract demonstrated significant hypolipidemic activity.^[42] Apart from its insulin sensitizing effect, *A. calamus* extract may have hypoglycemic effects via mechanisms of insulin releasing and alpha-glucosidase inhibition, and thus improves postprandial hyperglycemia and cardiovascular complications.^[43]
6. **Ativisa (*Aconitum heterophyllum* Wall.):** *Ativisha* (*Aconitum heterophyllum* wall) of family Ranunculaceae is an Ayurvedic herb which is known for its important medical properties. It is a tall herb and its roots are tuberous and paried. Based on morphology and anatomy, several forms of *A. heterophyllum* are recognized (white, Yellow, Black and Red) amongst which the white variety is the best.^[44] *Aconitum heterophyllum* is an endangered Himalayan plant. The subterranean part of the plant is used for the

treatment of diseases like nervous system disorders, fever, diarrhea, obesity, etc. The *A. heterophyllum* treatment markedly lowered total cholesterol, triglycerides and apolipoprotein B concentrations in blood serum. It also showed positive effects (increase) on serum high-density lipoprotein cholesterol (HDL-c) and apolipoprotein A1 concentrations. On the other hand, *A. heterophyllum* treatment lowered HMG- Co A activity, which helps to reduce endogenous cholesterol synthesis and also activated lecithin-cholesterol acyltransferase (LCAT), helping increase in HDL-c.^[45]

7. **Katurohani (*Picrorhiza kurroa* Royle ex Benth.):** Due to high Glycoside content it has potent anti-hyperlipidemic activity. The alcoholic, chloroform and aqueous root extracts of *P. kurroa* Royle ex Benth showed significant antihyperlipidemic activity in Triton wr- 1339 induced albino rats with Atorlip-20 as reference standard.^[46] It enhances the bile secretion through liver, improve the reestrification of long chain fatty acids and increase the production of HDL.
8. **Cirabilva (*Pongamia pinnata* Merr.):** *Cirabiva* is one among four varieties of *Karanja* - an ancient Ayurvedic herb described in Rigveda and Atharvaveda. It is mainly use to pacify *Kapha-Vata* *Dosha*. Methanolic extract of flower and pod of *P. pinnata* showed significant hypoglycemic activity in the Streptozotocin induced diabetic rats.^[47] Insulin deficiency or insulin resistance is associated with hypercholesterolemia and hypertriglyceridemia.^[48] *P. pinnata* pod and flower extract are found to significantly decrease the level of cholesterol, LDL, VLDL, triglycerides and increase the level of HDL. HDL improves the reverse cholesterol transport that further improves the removal of excessive cholesterol from non-hepatic tissues to liver thereby enhancing its excretion in the form of VLDL.
9. **Citraka (*Plumbago zeylanica* Linn.):** *P. zeylanica* Linn. extract is found to decrease intestinal cholesterol absorption and lower the activity of

lipogenic enzymes like HMG CoA reductase in the liver thus also helps in decreasing the cholesterologenesis. Additionally it also reduced the total lipid content in the liver. Moreover, the aqueous extract demonstrated a potential antioxidant capacity in DPPH and TBARS *in vitro* antioxidant assay.^[49]

10. Hemavati (*Iris versicolor*): It is a controversial drug because in Samhita the term *Hemavati* is also used for *Vaca* (*Acorus calamus*), but in this context *Vaca* is already described therefore *Iris versicolor* is taken for *Hemavati*. Very few scientific research studies are available for evaluating hypolipidemic effect of *Iris versicolor*. One such study showed its effect on norepinephrine stimulated fat cells where it increases the concentrations of glycerol and FFA further and increase in FFA can be accounted for the reduction in the process of reesterification. It is known that reesterification occurs concurrently with liberation of FFA during the process of lipolysis, and L. glycerophosphate is required. This result indicates that this has independent lipolytic effect on adipose tissue to mobilize fat. The lipolytic effect on adipose tissue may be directly and/or through catecholamines. There are evidences that central neuron system had ability to specifically control lipid mobilization without affecting glucose homeostasis. As for the neurochemistry is concerned, norepinephrine, released from brain neurons (by the action of drugs) mobilizes FFA in rats by activation of B receptors in the adipocyte plasma membrane.^[50]

11. Guggulu (*Commiphora mukul*): The gum resin of the *Commiphora mukul* is found to possess hypolipidemic activity. In an experiment, in-vitro administration of *Commiphora mukul* gum resin extract and medium-chain triglyceride found to significantly reduced low-density lipoprotein cholesterol and increased the high-density lipoprotein/low-density lipoprotein ratio. The combination showed direct inhibition of HMG-CoA reductase activity in a dose-dependent manner and compared very well with the

inhibitory effect of statins like Pravastatin and Mevastatin. The adipocyte differentiation was also inhibited. It is found to increased the AMPK α phosphorylation and AMPK kinase activity and inhibited the phosphorylated form of mTOR expression. It also highly upregulated the expression of LXR and PPAR α genes and moderately upregulated BABP and SHP genes.^[51]

12. Sunthi (*Zinziber officinalis*): It has been found that oral administration of ginger extract showed hypolipidemic effect in *Vanaspati* supplemented rats.^[52] Zinziber extract lowers the lipid level by disrupting the cholesterol absorption and also by inhibiting liver lipogenesis.^{[53],[54]} Evidence suggest that ginger contains antioxidant properties which have a hypocholesterolemic effect and anti-atherogenic and these activities might be attributed to the inhibition of LDL oxidation and the suppression on the activity of HMG-CoA (3-hydroxy-3methylglutaryl co-enzyme A) reductase.^[55] This also might occur due to the elevation of hepatic cholesterol 7-alpha-hydroxylase activity, which is a rate-limiting enzyme in the biosynthesis of the bile acids and stimulates the conversion of cholesterol to bile acids leading to the excretion of cholesterol from the body.^[56]

Use of Herbo- Mineral Preparation - Arogyavardhini Vati, a traditionally used Ayurvedic medicine may be a useful therapy for hypercholesterolemia through reducing oxidative stress (decreasing MDA and increasing GSH) and lipid levels. *Arogyavardhini Vati* significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of *Arogyavardhini Vati* (50, 100, 200 mg/kg) and fenofibrate - treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and *Arogyavardhini Vati* (200 mg/kg) treated rats when compared with normal control.^[57]

Panchakarma Procedures: Purificatory procedures of *Panchakarma* are extremely helpful in maintaining the homeostasis of lipids in blood.

Role of Vamana: Expulsion of vitiated *Doshas* through oral route is known as *Vamana*. Procedure of *Vamana* consist of following steps:

- **Step I - Deepan - Pachan** (use of carminative and digestive drugs) with *Panchakola Churna* (mixture of *Piper longum*, *Plumbago zeylanica*, *Zingiber officinale*, *Piper chaba* Hunter powder in equal amount) powder in the dose of 3gm given twice in day with lukewarm water-orally for 3 days.
- **Step II - Snehapan** (oleation therapy) with *Triphala Ghrita* - orally 3-7 days in the increasing order dose to be decided according to the *Koshtha*, *Prikriti*, *Satva* and *Agni* of the patients.
- **Step III - Vamana Karma** - Paste of *Madanphala Churna* - 5gm, *Vacha Churna* - 3gm, *Saindhav Lavana* - 2gm, *Madhu* - 5gm, Milk - 4 liter- orally - O.D /Madhuyasti Phanta/ nimbadi kwath - 3 liter-orally - O.D

Role of Lekhaniya Basti: *Lekhan basti* is mentioned by different Acharyas for *Kaphaja Roga* (diseases due to dyslipidemia, hypercholesterolemia) and *Kaphavrita Vata*. The word *Lekhana* itself indicates its action means - "*Lekhanam Karshanam*". Thus *Lekhan* is nothing but a process of emaciation while Sharangadhara considered *Lekhana* in a wide sense, i.e. *Lekhan* is a process of drying up or desiccation of all excess *Dosha*, *Dhatu* and *Mala* i.e. "*Deha Vishosanam*". The drugs of *Lekhan Basti* are described as follow,

1. **Kwatha Dravya** (drug used for decoction)- (a) *Triphala*- 30 gm (b) *Nagarmotha*-10gm (c) *Guduchi*- 10gm (d) *Amalthas*- 10 gm (e) *Madanphala* – 10 gm
2. **Kalka Dravya** (drug used for making paste): *Triphla churna* – 5gm *Yavakshar churna*- 5gm, *Pippali churna* – 5gm, *Madhuyasti churna*- 5 gm + *Madhu* -25 gm +*Sarshap Tail*- 50 ml + *Gomutra*- 150 ml

Note: These quantities are required for preparation of 300 ml of *Lekhaniya Basti*.

Rasayana Therapy: In *Charaka Samhita*, Acharya Charka descried a cluster of symptoms that appears due to faulty dietary habits, faulty life style and faulty thoughts what we know today as *Metabolic Syndrome*. Acharya says that excessive use of cultivated grains, vegetable, fruits and poultry products without appropriate work out (exercise), sedentary life style, unstable emotions like excessive fear, grief, greed, stress, etc. produces an array of syndrome that should be treated with *Rasayana* only.

The success of *Rasayana* therapy lies mainly in its multi-pronged approach in controlling health, while pacifying the disease. As any other therapy, this also has a set of rules to be adapted for its application. The outcome of *Rasayana* therapy depends upon the degree of adapting and observing these procedures. That includes *Purvakarma* (before procedures), *Pradhanakarma* (main procedure) and *Pashcatakarma* (after procedures).

Purva karma includes the *Samana* and *Sodhana Cikitsa*, to have a purified body (*Suddha Sharira*), in which a suitable *Rasayana Aushadha* can be administered. The administration of a suitable *Rasayana Aushadha* becomes the *Pradhana Karma* in the context of *Rasayana* therapy. During the *Rasayana* treatment and after the completion of the treatment, one has to adhere to the *Acara Rasayan* (moral ethics), which consists of instruction for using diet and life style after *Rasayana* therapy, this is known as *Pashcat Karma*. *Pashcat Karma* consists of *Parihara Kala*, which is twice the duration of *Pradhana Karma*. After the *Parihara Kala*, the individual is allowed to use normal diet.

Rasayana useful for Kaphaja Disorders

1. **Bhallataka (*Semecarpus anacardium* Linn):** Acharya Charaka says that there is no *Kaphaja* disorder on earth that can't be cured by *Bhallatak*. Acharya Charak describe *Kalpa* use of *Bhallatak* starting with 10 *Bhallatak* fruit, increasing one every day reaching upto 30 and then decreasing gradually to 10 *Bhallatak* thus total of 1000 *Bhallatak* can be used but never be more than this. The doses described by Acharya in

Samhitas are much more that can be tolerated by human in present time, therefore it is recommended that physician should modify the doses according to the patient strength.

Days	Doses of <i>Bhallatak</i>
1 st Day	Starting with 10 <i>Bhallatak</i>
2 nd Day- 21 th Day	Increasing 1 <i>Bhallatak</i> daily
21 th Day	30 <i>Bhallatak</i>
22 nd – 41 th Day	Decreasing 1 <i>Bhallatak</i> daily
41 th Day	10 <i>Bhallatak</i>
42 nd – 48 th Day	Increasing 1 <i>Bhallatak</i> daily
48 th Day	17 <i>Bhallatak</i>
49 th Day – 54 th Day	Decreasing 1 <i>Bhallatak</i> daily
54 th Day	11 <i>Bhallatak</i>
54 th and 55 th Day	11 <i>Bhallatak</i>
Total	1000 <i>Bhallatak</i>

Bhallatak should always be taken with milk to avoid mouth ulcers, gastritis etc. Acharaya Charak described 10 different dietary items of *Bhallatak* for use viz. milk, ghruta, honey, jaggery, etc.

2. *Shilajita (Asphaltum):* *Shilajita Rasayan* can be used in three ways – *Pravara* (maximum dose), *Madhyam* (moderate dose) and *Avara* (minimum dose). For maximum dose *Shilajita* is used in the dose of 4 *Tola* (= 46gm approx) for seven weeks, for moderate dose 2 *Tola* (=23gm approx) is used for three weeks and for minimum dose 1 *Tola* (=11.5gm approx). *Shilajita* is used for one week. During *Shilajita* use patient should be kept on milk diet.

3. *Pippali Rasayan (Piper longum):* For *Rasayan* purpose *Pippali* can be use in following methods:

- ***Pippali Vardhmana Kalpa*** - In this method dose of *Pippali* is escalated and then reduced gradually. For 10 days dose of *Pippali* powder is increased as 10 *Pippali* powder daily and then for 10 days its dose is reduced as 10 *Pippali* daily, thus total of 1000 *Pippali* is used keeping patient only on milk diet.
- ***Pippali Naimittika Rasayana*** - In this method, powder of 3 *Pippali* fruits is daily boiled with milk and taken empty stomach (method of preparation: *Pippali* powder + 250 ml of milk and 250ml of water boiled till only milk remains, then should be taken once in a day).
- Powder of 5,7,8 or 10 *Piper longum* fruit can be taken with honey and *Ghruta* for the purpose of *Rasayan*. *Piper longum* fruit is firstly soaked in *Palasha Kshara* and then dry to make powder. Powder of three *Pippali* should be taken in morning, before meal and after meal thrice time in a day for the desired effect of *Rasayan*.

Indication for using *Pippali Vardhamana Rasayana*

- a) Patients without any major complication (bleeding diathesis, gastritis, malena etc.)
- b) Patients with strong body built, strength, and good mental stamina (*Pravara Satva*).
- c) Should be used in patients with chronic liver diseases, liver cirrhosis, and other autoimmune liver disorders.


Indication for using *Pippali Naimittika Rasayana*

- a) Patients having complicated Cirrhosis (Cirrhosis with PHTN or Oesophageal varices).
- b) Those who cannot tolerate *Pippali vardhamana kalpa* and patients in which *vardhamana kalpa* is contraindicated.

4. *Triphala:* *Triphala* means powder of three fruits namely *Haritaki (Terminalia chebula)*, *Amalaki (Embllica Officinalis)* and *Bibhitaki (Terminalia Bellerica)*. For *Rasayan* purpose powder of one

Haritaki fruit should be taken after digestion of food (i.e. morning), powder of two *Bibhitaki* is taken before meal and powder of four *Amalaki* is taken after meal. *Triphala* paste painted around an iron utensil for whole night and then taken in morning with honey and water also work as *Rasayan* and is very useful in *Kaphaja* disorders. Equal amount of *Triphala* powder and *Madhuyasti* powder taken daily can also use for *Rasayan* purpose.

Fig. 5: Diagrammatic representation showing role of Lekhaniya drugs on Meda



CONCLUSION

Thus it is very clear that cholesterol has a definite role in insulin secretion through pancreatic B cell and hypolipidemic agents may prove beneficial in the management of diabetes. Use of herbs is the safest and cheapest way for scraping the accumulated cholesterol in the most natural manner. Purification therapy (*Panchakarma* therapy) and Rejuvenation therapies are very beneficial for disrupting the vicious cycle of hyperlipidemia and insulin resistance and prevent or minimize the complications.

REFERENCES

1. Sarah Wild, Gojka Roglic, Anders Green, Richard Sicree, Hilary King. *Diabetes Care*. 2004. 27 (5):1047-1053.

2. Cerf ME. Beta Cell Dysfunction and Insulin Resistance. *Frontiers in Endocrinology*. 2013;4:37.
3. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2009;32 (Suppl 1):S62-S67.
4. Bardini G, Rotella CM, Giannini S. Dyslipidemia and Diabetes: Reciprocal Impact of Impaired Lipid Metabolism and Beta-Cell Dysfunction on Micro- and Macrovascular Complications. *The Review of Diabetic Studies : RDS*. 2012;9(2-3):82-93.
5. Boden G. Obesity and Free Fatty Acids (FFA). *Endocrinology and metabolism clinics of North America*. 2008;37(3):635-ix.
6. Mingming Hao, W. Steven Head, Subhadra C. Gunawardana, Alyssa H. Hasty, David W. Piston. Direct Effect of Cholesterol on Insulin Secretion: A Novel Mechanism for Pancreatic -Cell Dysfunction. *Diabetes*. 2007.56(9):2328-38.
7. Le Lay S, Krief S, Farnier C, Lefrere I, Le Liepvre X, Bazin R, Ferre P, Dugail I. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. *Journal of Biological Chemistry*. 2001.18;276(20):16904-10.
8. P.L. Yeagle. Modulation of membrane function by cholesterol. *Biochimie*.1991. 73(10): 1303-1310.
9. Lodish H, Berk A, Zipursky SL, et al. *Molecular Cell Biology*. 4th edition. New York: W. H. Freeman; 2000. Section 5.3, Biomembranes: Structural Organization and Basic Functions. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK21583/>
10. KA Nave. Myelination and the trophic support of long axons. *Nature Reviews Neuroscience*. 2010.11: 275-283.
11. K Simons, E Ikonen. Functional rafts in cell membranes. *Nature*. 1997. 387: 569-572.
12. Wang YM, Zhang B, Xue Y, Li ZJ, Wang JF, Xue CH, Yanagita T. The mechanism of dietary cholesterol effects on lipids metabolism in rats. *Lipids Health Dis*. 2010 Jan 14;9:4.
13. DeBose-Boyd RA. Feedback Regulation of Cholesterol Synthesis: Sterol-Accelerated Ubiquitination and Degradation of HMG CoA Reductase. *Cell research*. 2008;18(6):609-621. doi:10.1038/cr.2008.61.
14. Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. *The Journal of Clinical Investigation*. 2008;118(2):403-408. doi:10.1172/JCI33296.

15. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontés G. Glucolipototoxicity of the Pancreatic Beta Cell. *Biochimica et biophysica acta*. 2010;1801(3):289-298. doi:10.1016/j.bbali.2009.08.006.
16. Bogan, J. S., Xu, Y. and Hao, M. (2012), Cholesterol Accumulation Increases Insulin Granule Size and Impairs Membrane Trafficking. *Traffic*. 2012. 13: 1466–1480.
17. Fryirs M, Barter PJ, Rye KA. Cholesterol metabolism and pancreatic beta-cell function. *Current Opinion in Lipidology*. 2009.20(3):159-64.
18. Langhi C, Cariou B. Cholesterol metabolism and beta-cell function. *Medicine Science*. 2010. 26(4):385-90.
19. Shukla VD, Tripathi RD. Agnivesha, Charaka Samhita, Vaidyamanorama Hindi Commentary. Delhi, India; Chaukhamba Sanskrit Pratisthana, 2002.
20. R. S. Chandratre, S. Chandarana, S. A. Mengi. Lipid Lowering Activity of Alcoholic Extract of *Cyperus Rotundus*. *IJRPC* 2011, 1(4): 1042-45.
21. G. N. Okwu1, S. E. Abanobi, U. V. Nnadi, C. O. Ujowundu, A. C. Ene. Hypolipidemic Properties of Ethanol Extract of *Cyperus rotundus* Rhizome. *International Journal of Biochemistry Research and Review* 7(3): 132-138, 2015.
22. KR. Nagulendran, R. Mahesh, V. Hazeena Begum. Preventive role of *Cyperus rotundus* rhizomes extract on age associated changes in glucose and lipids. *Pharmacologyonline* 2: 318-325 (2007).
23. Jones PJH, MacDougall DE, Ntanios F, Vanstone CA. Dietary phytosterols as cholesterol-lowering agents in humans. *Can J Physiol Pharmacol* 1997;75:217-227.
24. Kang SY, Kim SH, Schini VB, Kim ND. Dietary ginsenosides improve endothelium-dependent relaxation in the thoracic aorta of hypercholesterolemic rabbit. *Gen Pharmacol* 1995;26:483-487.
25. Chen HC, Chou CK, Lee SD, Wang JC, Yeh SF. Active compounds from *Saussurea lappa* Clarks that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells. *Antiviral Res*.1995;27:99–109.
26. Ambavade SD, Mhetre NA, Tate VD, Bodhankar SL. Pharmacological evaluation of anxiolytic effect of aqueous extracts of *Saussurea lappa* roots in mice. *Eur J Integr Med*. 2009;1:131–7.
27. J. Anbu, A. Anjana, K. Purushothaman, M. Sumithra, S. Suganya, N. Kumar Bathula. Evaluation of Antihyperlipidemic Activity of Ethanol Extract of *Saussurea lappa* in Rats. *International Journal of Pharma and Bio Sciences*. 2011; 2(4) : 550-56.
28. Khare CP. *Indian Medicinal Plants: An Illustrated Dictionary*. Berlin: Springer-verlag; 2007. *Saussurea lappa*; pp. 586–7.
29. Shah NC. Herbal folk medicines in Northern India. *J Ethnopharmacol*. 1982;6:293–301.
30. Sircar NN. Pharmacotherapy of dasemani drugs. *Anc Sci Life*. 1984;3:132–5.
31. Lechner-Knecht S. Sacred healing plants in Nepal. *Dtsch Apoth Ztg*. 1982; 122:2122–9.
32. Babu PS, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric (*Curcuma longa*) in streptozotocin induced diabetic rats. *Molecular Cell Biochemistry*. 1997 Jan;166(1-2):169-75.
33. *Lekhani Pashine, J V Singh, A K Vaish, S K Ojha, A A Mahdi*. Effect of Turmeric (*Curcuma longa*) on Overweight Hyperlipidemic Subjects: Double Blind Study. *Indian Journal of Community Health*. 2012; 24 (2): 113-17.
34. Rao DS, Sekhara NC, Satyanarayana MN, Srinivasan M. Effect of curcumin on serum and liver cholesterol levels in the rat. *J. Nutr*. 1970; 100 (11), 1307–1315.
35. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. *J Nutr*. 2001; 131(11): 2932-2935.
36. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. *Atherosclerosis*. 1999; 147(2): 371-378.
37. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. *Acta Med Indones*. 2008; 40(4): 201-210.
38. F. A. Razaq, R. A. Khan, Z. Feroz, S. Afroz. Effect of *Berberis aristata* on lipid profile and coagulation parameters. *African Journal of Pharmacy and Pharmacology*. 2011;5(7): 943-947.
39. Sharma SB, Hasir A, Prabhu KM, Murthy PS, Dwv G. Hypoglycemic and Hypolipidemic effect of ethanolic extracts of seeds of *Eugenia Jambolona* in Alloxan induced Diabetic rabbits. *Journal of Ethanopharmacology* 2003; 85: 201-206.

40. N. K. Upwar, R. Patel, N. Waseem, N. K. Mahobia. Hypoglycemic Effect of Methanolic Extract of Berberis Aristata DC Stem on Normal and Streptozotocin Induced Diabetic Rats. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3(1): 222-24.
41. P.K. Mukherjee, V. Kumar, M.Mal, Peter J. Houghton. *Acorus calamus*.: Scientific Validation of Ayurvedic Tradition from Natural Resources. Pharmaceutical Biology. 2007; 45(8): 651-66.
42. R.S. Parab, S.A. Mengi. Hypolipidemic activity of *Acorus calamus* L. in rats. Fitoterapia. 2002; 73(6): 451-55.
43. Mei-mei Si, Jian-shu Lou, Chang-Xin Zhou, Juan-Na Shen, Hong-Hai Wu, Bo Yang, et. al. Insulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of *Acorus calamus* *in vitro* and *in vivo*. Journal of Ethnopharmacology. 2010; 128(1): 154-159.
44. M.D. Ukani, N.K Mehta, D.D Nanavati. Aconitum Heterophyllum (Ativisha) in Ayurveda. Ancient Science of life. 1996; 26: 166 -171.
45. A.K.Subash, A.Augustine. Hypolipidemic effect of methanol fraction of Aconitum heterophyllum wall ex Royle and the mechanism of action in diet-induced obese rats. Journal of Advance Pharmaceutical and Technology Research. 2012 ;3(4):224-8.
46. V. Singh, A. Chaudhary, Gunjan. Anti-hyper lipidemic activity of Picrorhiza kurroa Royle ex Benth Roots. International Journal of Drug Development and Research. 2012; 4(3): 88-91.
47. P. Kumar, A. Semalty, S.R. Mir, M. Ali and S. Amin, 2010. Hypoglycemic and Hypolipidemic Activity of Pongamia pinnata (Linn.) Pierre in Streptozotocin-induced Diabetic Rats. International Journal of Pharmacology, 6: 738-743.
48. Sharma, S.R., S.K. Dwivedi and D. Swarup, 1996. Hypoglycaemic and hypolipidemic effects of cinnamomum tamala Nees leaves. Indian J. Exp. Biol., 34: 372-374.
49. Sudha R. Pendurkar, Sushma A. Mengi. Antihyperlipidemic effect of aqueous extract of *Plumbago zeylanica* roots in diet-induced hyperlipidemic rat. Pharmaceutical Biology. 2009;47(10): 1004-1010.
50. Effect of Some Medicinal Plant Preparations of Adipose Tissue Metabolism. Bambhole, V.D. Ancient Science of Life. 1988; 8(2): 117-124.
51. C. Ramachandran, Smitha M. Nair, Karl-W. Quirrin, Steven J. Melnick. Hypolipidemic Effects of a Proprietary Commiphora Mukul Gum Resin Extract and Medium-Chain Triglyceride Preparation (GU-MCT810). Journal of Evidence-Based Complementary and Alternative Medicine. 2013; 18 (4): 248-256.
52. P.Paul, M.K.Islam, A.Mustari, M.Z.I.Khan. Hypolipidemic Effect of Ginger Extract in Vanaspati Fed Rats. Bangladesh Journal of Veterinary Medicine. 2012; 10(1and2): 93-96.
53. Newall CA, Anderson LA, Philpson JD (1996). Herbal Medicine: A Guide for Health Care professionals. The Pharmaceutical Press, London, UK. pp. 135-137.
54. Tanabe M, Chen YD, Saito K, Kano Y(1993). Cholesterol biosynthesis inhibitory component from Zingiber officinale. Chemical and pharmaceutical bulletin 41: 710-713.
55. Ahmed RS, Seth V and Banerjee BD (2000). Influence of dietary ginger (Zingiber officinale) on the antioxidant defense system in rat: comparison with ascorbic acid. Indian Journal of Experimental Biology 38: 604-606.
56. Srinivasan K, Sambaiah K (1991). The effect of spices on cholesterol 7 alpha-hydroxylase activity and on serum and hepatic cholesterol levels in the rat. International Journal for Vitamin and Nutrition Research 61: 364-369.
57. G. Kumar, A. Srivastava, S.K.Sharma, Y.K.Gupta. The hypolipidemic activity of Ayurvedic medicine, *Arogyavardhini vati* in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate. Journal of Ayurveda and Integrative Medicine. 2013 Jul-Sep; 4(3): 165-170.

How to cite this article: Divya Kajaria. Cholesterol & its Ayurvedic Complement – Depicting its role in Pathogenesis as well as Management of Diabetes. J Ayurveda Integr Med Sci 2017;3:124-136. <http://dx.doi.org/10.21760/jaims.v2i3.8220>

Source of Support: Nil, **Conflict of Interest:** None declared.
